Sarepta Therapeutics (SRPT) 21.37 $SRPT
Catabasis' DMD Drug in Phase II Open-Label Extension Study
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:28AM CDT
Catabasis (CATB) initiated an open-label extension for the phase II portion (Part
of its MoveDMD study on edasalonexent for the treatment of DMD.
BMRN: 88.59 (-2.90), CATB: 3.76 (+0.07), GWPH: 96.35 (+1.52), SRPT: 21.37 (-1.25)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 252.54 (+1.24), BMRN: 88.59 (-2.90), SRPT: 21.37 (-1.25), ALXN: 125.30 (+0.88), IBB: 270.56 (-0.57), REGN: 375.74 (-2.61)
Sarepta Therapeutics Announces Common Stock Offering
BusinessWire - Thu Jun 09, 6:00AM CDT
Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W. Baird & Co., agreed to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering, before deducting underwriting discounts and commission and other estimated offering expenses.
SRPT: 21.37 (-1.25)
Sarepta Therapeutics Announces Proposed Offering
BusinessWire - Wed Jun 08, 3:19PM CDT
Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W. Baird & Co., intends to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering, before deducting underwriting discounts and commission and other estimated offering expenses.
SRPT: 21.37 (-1.25)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 252.54 (+1.24), SRPT: 21.37 (-1.25), ALXN: 125.30 (+0.88), AMGN: 160.18 (-0.92), ABBV: 64.35 (+0.19), REGN: 375.74 (-2.61), CELG: 103.41 (-1.62)
Sarepta Asked to Provide Dystrophin Data on Eteplirsen
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:23AM CDT
Sarepta (SRPT) announced that the FDA has requested for dystrophin data from biopsies on eteplirsen, as part of the ongoing evaluation of the NDA.
BMRN: 88.59 (-2.90), SRPT: 21.37 (-1.25), PFE: 36.15 (+0.03), BMY: 75.39 (+0.11)
Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
BusinessWire - Mon Jun 06, 4:40PM CDT
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA). The Company plans to submit data from thirteen patient biopsy samples, at baseline and Week 48, to the FDA over the coming weeks to facilitate a prompt decision on the NDA by the Agency.
SRPT: 21.37 (-1.25)
Why Is Sarepta Therapeutics (SPRT) Stock Down 20% Today?
Ryan McQueeney - Zacks Investment Research - Thu Jun 02, 12:11PM CDT
Shares of Sarepta Therapeutics (SRPT) fell nearly 20% in early morning trading Thursday after new reports suggested that the Food and Drug Administration may force the company to offer its Duchenne muscular dystrophy (DMD) drug to patients at cost.
SRPT: 21.37 (-1.25)
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
BIIB: 252.54 (+1.24), SRPT: 21.37 (-1.25), ICPT: 151.73 (unch), ABBV: 64.35 (+0.19), IONS: 25.28 (-0.08)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 252.54 (+1.24), VRTX: 90.10 (+1.14), GILD: 86.25 (-0.30), SRPT: 21.37 (-1.25), ICPT: 151.73 (unch), ABBV: 64.35 (+0.19), IONS: 25.28 (-0.08)
Pre-Market Technical Breakdown Highlights on Biotech Stocks
ACCESSWIRE - Wed Jun 01, 8:16AM CDT
LONDON, UK / ACCESSWIRE / June 1, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Gilead Sciences, Baxalta, MannKind, and Sarepta Therapeutics.
GILD: 86.25 (-0.30), SRPT: 21.37 (-1.25), BXLT: 46.02 (-0.18), MNKD: 1.14 (-0.03)
BioMarin Withdraws Kyndrisa Marketing Application in EU
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 6:49AM CDT
BioMarin (BMRN) has withdrawn its regulatory application for Kyndrisa from the EU, following discussions with the EMA's CHMP.
BMRN: 88.59 (-2.90), ANIP: 55.38 (-1.13), SRPT: 21.37 (-1.25), BMY: 75.39 (+0.11)
Why is Sarepta Therapeutics (SRPT) Stock Soaring 20% Today?
Madeleine Johnson - Zacks Investment Research - Wed May 25, 12:35PM CDT
On Wednesday, shares of Sarepta Therapeutics (SRPT) are soaring, up almost 20% in afternoon trading on news that the company announced that the Food & Drug Administration (FDA) has delayed ruling in its drug eteplirsen.
SRPT: 21.37 (-1.25)
FDA delay raises slim hope for muscular dystrophy drug
By MATTHEW PERRONE - AP - Wed May 25, 11:23AM CDT
WASHINGTON (AP) — Federal health regulators will take more time to review a highly-contested drug for muscular dystrophy that has become a flashpoint in the debate over patient access to experimental medicine.
SRPT: 21.37 (-1.25)
Sarepta Therapeutics Announces FDA Will Not Complete the Review of the Eteplirsen New Drug Application By The PDUFA Date
BusinessWire - Wed May 25, 6:00AM CDT
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that they are continuing their review and internal discussions related to our pending NDA for eteplirsen and will not be able to complete their work by the Prescription Drug User Fee Act (PDUFA) goal date of May 26, 2016. The FDA has communicated that they will continue to work past the PDUFA goal date and strive to complete their work in as timely a manner as possible.
SRPT: 21.37 (-1.25)
Cytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors
GlobeNewswire - Fri May 20, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Edward M. Kaye, M.D., has been appointed to the company's Board of Directors. Dr. Kaye is the Interim Chief Executive Officer and Senior Vice President, Chief Medical Officer of Sarepta Therapeutics.
CYTK: 10.09 (-0.24), SRPT: 21.37 (-1.25)
CORRECTING and REPLACING Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinessWire - Tue May 10, 4:08PM CDT
Please replace the release dated February 2, 2016 with the following corrected version due to multiple revisions.
SRPT: 21.37 (-1.25)
Third Annual BLINGO Raises $200,000 for CureDuchenne
BusinessWire - Fri May 06, 11:19AM CDT
On Saturday, April 30th, CureDuchenne, a national nonprofit that raises awareness and funds for research to find a cure for Duchenne Muscular Dystrophy, hosted a "blinged-out" event at The Logan Hotel--featuring special bingo callers including FOX29 News General Assignment Reporter, Jennaphr Frederick, former Governor Edward G. Rendell, WMMR Preston and Steve show producer, Marisa Magnatta, local sensation John Bolaris, and comedian Joe Conklin in celebration for a cause to help save the lives of those with Duchenne.
SRPT: 21.37 (-1.25)
Sarepta Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 6:24AM CDT
CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Thursday reported a loss of $59.8 million in its first quarter.
SRPT: 21.37 (-1.25)
Catabasis' DMD Drug in Phase II Open-Label Extension Study
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 9:28AM CDT
Catabasis (CATB) initiated an open-label extension for the phase II portion (Part
of its MoveDMD study on edasalonexent for the treatment of DMD. BMRN: 88.59 (-2.90), CATB: 3.76 (+0.07), GWPH: 96.35 (+1.52), SRPT: 21.37 (-1.25)
4 Stocks That Crushed the Biotechnology ETF (IBB) This Week
Eric Dutram - Zacks Investment Research - Fri Jun 10, 12:15PM CDT
It was a rough week for the biotechnology ETF (IBB). Which stocks pushed this key sector fund lower for the week?
BIIB: 252.54 (+1.24), BMRN: 88.59 (-2.90), SRPT: 21.37 (-1.25), ALXN: 125.30 (+0.88), IBB: 270.56 (-0.57), REGN: 375.74 (-2.61)
Sarepta Therapeutics Announces Common Stock Offering
BusinessWire - Thu Jun 09, 6:00AM CDT
Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W. Baird & Co., agreed to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering, before deducting underwriting discounts and commission and other estimated offering expenses.
SRPT: 21.37 (-1.25)
Sarepta Therapeutics Announces Proposed Offering
BusinessWire - Wed Jun 08, 3:19PM CDT
Sarepta Therapeutics, Inc. (Nasdaq: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that Sarepta, through Credit Suisse and Robert W. Baird & Co., intends to sell an amount of its common stock equal to approximately $37.5 million in gross proceeds in an underwritten offering, before deducting underwriting discounts and commission and other estimated offering expenses.
SRPT: 21.37 (-1.25)
Biotech Stock Roundup: Biogen Slips on MS Results, ASCO Data in Focus
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 1:38PM CDT
Although focus was on data presentation at ASCO, investors were disappointed with Biogen's (BIIB) results on its highly-watched multiple sclerosis treatment.
BIIB: 252.54 (+1.24), SRPT: 21.37 (-1.25), ALXN: 125.30 (+0.88), AMGN: 160.18 (-0.92), ABBV: 64.35 (+0.19), REGN: 375.74 (-2.61), CELG: 103.41 (-1.62)
Sarepta Asked to Provide Dystrophin Data on Eteplirsen
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 8:23AM CDT
Sarepta (SRPT) announced that the FDA has requested for dystrophin data from biopsies on eteplirsen, as part of the ongoing evaluation of the NDA.
BMRN: 88.59 (-2.90), SRPT: 21.37 (-1.25), PFE: 36.15 (+0.03), BMY: 75.39 (+0.11)
Sarepta Therapeutics Announces FDA Request For Dystrophin Data Prior To Making A Decision on Eteplirsen NDA
BusinessWire - Mon Jun 06, 4:40PM CDT
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has requested that Sarepta provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen (PROMOVI), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA). The Company plans to submit data from thirteen patient biopsy samples, at baseline and Week 48, to the FDA over the coming weeks to facilitate a prompt decision on the NDA by the Agency.
SRPT: 21.37 (-1.25)
Why Is Sarepta Therapeutics (SPRT) Stock Down 20% Today?
Ryan McQueeney - Zacks Investment Research - Thu Jun 02, 12:11PM CDT
Shares of Sarepta Therapeutics (SRPT) fell nearly 20% in early morning trading Thursday after new reports suggested that the Food and Drug Administration may force the company to offer its Duchenne muscular dystrophy (DMD) drug to patients at cost.
SRPT: 21.37 (-1.25)
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: Sarepta, Biogen, AbbVie, Intercept and Ionis
BIIB: 252.54 (+1.24), SRPT: 21.37 (-1.25), ICPT: 151.73 (unch), ABBV: 64.35 (+0.19), IONS: 25.28 (-0.08)
Biotech Stock Roundup: Sarepta Shoots Up on FDA Delay, Ionis Falls on Pipeline News
Arpita Dutt - Zacks Investment Research - Wed Jun 01, 1:40PM CDT
With the annual meeting of ASCO coming up, watch out for updates from several biotech companies on their cancer treatments.
BIIB: 252.54 (+1.24), VRTX: 90.10 (+1.14), GILD: 86.25 (-0.30), SRPT: 21.37 (-1.25), ICPT: 151.73 (unch), ABBV: 64.35 (+0.19), IONS: 25.28 (-0.08)
Pre-Market Technical Breakdown Highlights on Biotech Stocks
ACCESSWIRE - Wed Jun 01, 8:16AM CDT
LONDON, UK / ACCESSWIRE / June 1, 2016 / ActiveWallSt.com announces the list of stocks featured in the Technical Morning Blog. Every morning the Active Wall St. team discusses the latest news and technical events impacting stocks and the financial markets. Companies recently featured in the blog include Gilead Sciences, Baxalta, MannKind, and Sarepta Therapeutics.
GILD: 86.25 (-0.30), SRPT: 21.37 (-1.25), BXLT: 46.02 (-0.18), MNKD: 1.14 (-0.03)
BioMarin Withdraws Kyndrisa Marketing Application in EU
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 6:49AM CDT
BioMarin (BMRN) has withdrawn its regulatory application for Kyndrisa from the EU, following discussions with the EMA's CHMP.
BMRN: 88.59 (-2.90), ANIP: 55.38 (-1.13), SRPT: 21.37 (-1.25), BMY: 75.39 (+0.11)
Why is Sarepta Therapeutics (SRPT) Stock Soaring 20% Today?
Madeleine Johnson - Zacks Investment Research - Wed May 25, 12:35PM CDT
On Wednesday, shares of Sarepta Therapeutics (SRPT) are soaring, up almost 20% in afternoon trading on news that the company announced that the Food & Drug Administration (FDA) has delayed ruling in its drug eteplirsen.
SRPT: 21.37 (-1.25)
FDA delay raises slim hope for muscular dystrophy drug
By MATTHEW PERRONE - AP - Wed May 25, 11:23AM CDT
WASHINGTON (AP) — Federal health regulators will take more time to review a highly-contested drug for muscular dystrophy that has become a flashpoint in the debate over patient access to experimental medicine.
SRPT: 21.37 (-1.25)
Sarepta Therapeutics Announces FDA Will Not Complete the Review of the Eteplirsen New Drug Application By The PDUFA Date
BusinessWire - Wed May 25, 6:00AM CDT
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that they are continuing their review and internal discussions related to our pending NDA for eteplirsen and will not be able to complete their work by the Prescription Drug User Fee Act (PDUFA) goal date of May 26, 2016. The FDA has communicated that they will continue to work past the PDUFA goal date and strive to complete their work in as timely a manner as possible.
SRPT: 21.37 (-1.25)
Cytokinetics Appoints Edward M. Kaye, M.D., to Board of Directors
GlobeNewswire - Fri May 20, 3:00PM CDT
Cytokinetics, Inc. (Nasdaq:CYTK) announced today that Edward M. Kaye, M.D., has been appointed to the company's Board of Directors. Dr. Kaye is the Interim Chief Executive Officer and Senior Vice President, Chief Medical Officer of Sarepta Therapeutics.
CYTK: 10.09 (-0.24), SRPT: 21.37 (-1.25)
CORRECTING and REPLACING Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BusinessWire - Tue May 10, 4:08PM CDT
Please replace the release dated February 2, 2016 with the following corrected version due to multiple revisions.
SRPT: 21.37 (-1.25)
Third Annual BLINGO Raises $200,000 for CureDuchenne
BusinessWire - Fri May 06, 11:19AM CDT
On Saturday, April 30th, CureDuchenne, a national nonprofit that raises awareness and funds for research to find a cure for Duchenne Muscular Dystrophy, hosted a "blinged-out" event at The Logan Hotel--featuring special bingo callers including FOX29 News General Assignment Reporter, Jennaphr Frederick, former Governor Edward G. Rendell, WMMR Preston and Steve show producer, Marisa Magnatta, local sensation John Bolaris, and comedian Joe Conklin in celebration for a cause to help save the lives of those with Duchenne.
SRPT: 21.37 (-1.25)
Sarepta Therapeutics reports 1Q loss
Automated Insights - Thu May 05, 6:24AM CDT
CAMBRIDGE, Mass. (AP) _ Sarepta Therapeutics Inc. (SRPT) on Thursday reported a loss of $59.8 million in its first quarter.
SRPT: 21.37 (-1.25)
